# Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.

> **NCT00040443** · PHASE2 · COMPLETED · sponsor: **RespireRx** · enrollment: 175 (actual)

## Conditions studied

- Mild Cognitive Impairment

## Interventions

- **DRUG:** CX516
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00040443
- **Lead sponsor:** RespireRx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** 2003-08
- **Final completion:** 2004-06
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2018-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00040443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00040443, "Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00040443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*